AZR · Azora Therapeutics, Inc. (DE) · Documents

Azora Therapeutics appointed Matthew Davidson as CEO, Celia Economides as CFO and Julie Saiki as chief strategy officer. Stockholders increased authorized shares from 100,000,000 to 500,000,000 and approved preferred-stock conversion; Nasdaq trading is expected under “AZR” on October 29, 2026.

Adial acquired Azora Therapeutics, received approximately $24.3 million net in initial financing proceeds, and targets AT177 IND and Phase 1a initiation in first half of 2027; recurring losses raise substantial doubt about its going concern.

Adial Pharmaceuticals, Inc. registers proposed resale of 25,148,970 common shares by selling stockholders, tied to its Azora acquisition and related PIPE and noteholder warrants. Stockholder approval is required by December 11, 2026, or significant cash payments could be owed.

Adial Pharmaceuticals, Inc. disclosed that its 2026 Annual Meeting was further adjourned on October 15, 2026 with respect to Proposals 3, 4, 5 and 6, pending approval of its Listing Application, and will reconvene on October 26, 2026.

Adial Pharmaceuticals further adjourned its 2026 Annual Meeting on October 15, 2026 with respect to Proposals 3, 4, 5 and 6 because Nasdaq had not approved the Listing Application; polls remain open and the meeting will reconvene on October 26, 2026 at 8:30 a.m. Eastern Time.

Adial Pharmaceuticals, Inc. further adjourned votes on Proposals 3, 4, 5 and 6 at its 2026 Annual Meeting pending Nasdaq approval, keeping polls open and scheduling reconvening for October 15, 2026 at 8:30 a.m. Eastern Time.

Adial Pharmaceuticals, Inc. further adjourned votes on Proposals 3, 4, 5 and 6 pending Nasdaq approval; polls remain open until reconvening October 15, 2026 at 8:30 a.m. Eastern Time.